Myeloma-Developing Regimens Using Genomics (MyDRUG)



Status:Not yet recruiting
Conditions:Hematology, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:3/8/2019
Start Date:March 15, 2019
End Date:February 10, 2024
Contact:MMRF Patient Support Center
Email:patientnavigator@themmrf.org
Phone:866-603-6628

Use our guide to learn which trials are right for you!

Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)

The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted
to affect specific genes that are mutated as part of the disease. Mutations in genes can lead
to uncontrolled cell growth and cancer. Patients with a greater than 30% mutation to any of
the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled
to one of the treatment arms. These arms have treatments specifically directed to the mutated
genes. Patients that do not have a greater than 30% mutation to the genes listed can be
enrolled to a non-actionable treatment arm.

The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002
study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related
Plasma Cell Malignancies. (NCT02884102).

The study will enroll 228 patients enrolled to one of six treatment arms. The study is open
to patients relapsing with relapsed refractory multiple myeloma, who have

- received at least one prior but no more than 3 prior therapies

- exposed to both a PI and an IMiD

- had early relapse after initial treatment. Relapse is defined as the IMWG uniform
response criteria (Kumar et al, 2016). Early relapse as defined by at least one of the
following:

1. Relapse within 3 years post autologous stem cell transplantation (ASCT) on
maintenance, or 18 months if unmaintained

2. Relapse within 18 months of initial non-ASCT based therapy

Inclusion Criteria:

- Willing to be registered into the pomalidomide (POMALYST®) Risk Evaluation and
Mitigation Strategy (REMS®) program

- Enrolled in the MMRF002 Molecular Profiling Protocol (NCT02884102) with report less
than 120 days old

- Disease free of prior malignancies for ≥ 3 years with exception of currently treated
basal cell, squamous cell carcinoma of the skin, carcinoma "in situ" of the cervix or
breast, or prostate cancer not requiring therapy

- High risk patients with relapsed refractory multiple myeloma (RRMM), who have:

- received at least one prior but no more than 3 prior therapies

- exposed to both a PI and an IMiD

- had early relapse after initial treatmentEarly relapse as defined by at least one
of the following: (Relapse is defined as the IMWG uniform response)

1. Within 3 years post autologous stem cell transplantation (ASCT) on
maintenance, or 18 months if unmaintained

2. Within 18 months of initial non-ASCT based therapy

- Patients must have progressed after their most recent treatment and require therapy
for myeloma

- Females of reproductive potential must have a negative pregnancy test at baseline, be
non-lactating, and willing to adhere to scheduled pregnancy testing

- Females of reproductive potential and males must practice and acceptable method of
birth control

- Laboratory values obtained ≤ 14 days prior to registration:

- Absolute neutrophil count (ANC) ≥ 1000/ul

- Hemoglobin (Hgb) ≥ 8 g/dl

- Platelet (PLT) ≥ 75,000/ul

- Total bilirubin <1.5 x upper limit of normal (ULN) or if total bilirubin is >1.5
x ULN, the direct bilirubin must be ≤ 2.0 mg/dL

- Aspartate aminotransferase (AST) <3 x ULN

- Creatinine Clearance ≥ 30 mL/min

Measurable disease of Multiple Myeloma (MM) as defined by at least one of the following:

- Serum monoclonal protein ≥1.0 g by protein electrophoresis

- ≥200 mg of monoclonal protein in the urine on 24-hour electrophoresis

- Serum immunoglobulin free light chain (FLC) ≥10 mg/dL AND abnormal serum
immunoglobulin kappa to lambda FLC ratio

- Monoclonal bone marrow plasmacytosis ≥30% (evaluable disease)

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2

- Ability to take aspirin, warfarin, or low molecular weight heparin

Sub-Protocol Inclusion Criteria:

Refer to each respective Sub Protocol for additional inclusion criteria.

Exclusion Criteria:

Patients will be ineligible for this study if they meet any one of the following criteria:

- Aggressive multiple myeloma requiring immediate treatment as defined by:

- Lactate dehydrogenase (LDH) > 2 times ULN

- Presence of symptomatic extramedullary disease or central nervous system
involvement

- Hypercalcemia >11.5 mg/dl

- Acute worsening of renal function (CrCl < 30 ml/min) directly related to myeloma
relapse

- Any neurological emergency related to myeloma

- Clinical symptoms of hyperviscosity related to monoclonal protein

- Involved serum free light chain > 100 mg/dL (1000 mg/L) in the setting of prior
diagnosis of cast nephropathy

- Infection requiring systemic antibiotic therapy or other serious infection within 14
days of enrolment

- Known hypersensitivity or development of erythema nodosum if characterized by a
desquamating rash while taking thalidomide, lenalidomide, pomalidomide or similar
drug. Known allergy to any of the study medications, their analogues, or excipients in
the various formulations of the agents

- Prior Ixazomib/Pomalidomide/Dexamethasone combination therapy

- Pregnant or breast-feeding females

- Serious medical or psychiatric illness, active alcoholism, or drug addiction that may
hinder or confuse compliance, interfere in the completion of treatment per protocol,
or follow-up evaluation

- Active hepatitis A, B or C viral infection or known human immunodeficiency virus (HIV)
infection

- Concurrent symptomatic amyloidosis or plasma cell leukemia

- POEMS syndrome [plasma cell dyscrasia with polyneuropathy, organomegaly,
endocrinopathy, monoclonal protein (M-protein) and skin changes]

- Residual side effects to previous therapy > Grade 1 prior to initiation of therapy
(Alopecia any grade and/or neuropathy Grade 2 without pain are permitted)

- Prior allogeneic or ASCT within 12 weeks of initiation of therapy. Prior allogeneic
stem cell transplant with active graft-versus-host disease (GVHD)

- Prior experimental therapy within 14 days of protocol treatment or 5 half-lives of the
investigational drug, whichever is longer

- Prior anticancer therapy within 14 days of initiation of protocol therapy
(Dexamethasone/ 40mg/day) for a maximum of 4 days before screening is allowed

- Prior major surgical procedure or radiation therapy within 4 weeks of the initiation
of therapy (this does not include limited course of radiation used for management of
bone pain within 7 days of initiation of therapy).

- Known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that
limit the ingestion or Gastro Intestinal (GI) absorption of drugs administered orally

- Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,
unstable angina, or myocardial infarction within the past 6 months

- Other co-morbidity, which would interfere with patient's ability to participate in
trial or that confounds the ability to interpret data from the study

Sub-Protocol Exclusion Criteria:

Refer to each respective Sub Protocol for additional exclusion criteria.
We found this trial at
17
sites
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health System The University of Michigan is home to one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02215
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charlotte, North Carolina 28211
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
8503 Arlington Blvd., Ste. 400
Fairfax, Virginia 22031
(703) 280-5390
Virginia Cancer Specialists, PC Now the world's most advanced cancer treatment capabilities can be found...
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Phoenix, Arizona 85054
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials